Back to Search Start Over

OPtimising Treatment for MIld Systolic hypertension in the Elderly (OPTiMISE): protocol for a randomised controlled non-inferiority trial

Authors :
Eleanor Temple
John M. Benson
Sue Jowett
Emma Ogburn
FD Richard Hobbs
Ly-Mee Yu
Rupert Payne
Richard J McManus
Jonathan Mant
Paul Little
Marney Williams
Mark Lown
Jenni Burt
Alecia Nickless
Jill Mollison
Gary A. Ford
Carl Heneghan
James P Sheppard
Sheppard, James P [0000-0002-4461-8756]
Burt, Jenni [0000-0002-0037-274X]
Heneghan, Carl [0000-0002-1009-1992]
Yu, Ly-Mee [0000-0003-0331-7364]
McManus, Richard J [0000-0003-3638-028X]
Apollo - University of Cambridge Repository
Source :
Sheppard, J P, Burt, J, Lown, M, Temple, E, Benson, J, Ford, G A, Heneghan, C, Hobbs, F D R, Jowett, S, Little, P, Mant, J, Mollison, J, Nickless, A, Ogburn, E, Payne, R, Williams, M, Yu, L-M & McManus, R J 2018, ' OPtimising Treatment for MIld Systolic hypertension in the Elderly (OPTiMISE) : protocol for a randomised controlled non-inferiority trial ', BMJ Open, vol. 8, no. 9, e022930 . https://doi.org/10.1136/bmjopen-2018-022930, BMJ Open
Publication Year :
2018
Publisher :
BMJ, 2018.

Abstract

IntroductionRecent evidence suggests that larger blood pressure reductions and multiple antihypertensive drugs may be harmful in older people, particularly frail individuals with polypharmacy and multimorbidity. However, there is a lack of evidence to support deprescribing of antihypertensives, which limits the practice of medication reduction in routine clinical care. The aim of this trial is to examine whether antihypertensive medication reduction is possible in older patients without significant changes in blood pressure control at follow-up.Methods and analysisThis trial will use a primary care-based, open-label, randomised controlled trial design. A total of 540 participants will be recruited, aged ≥80 years, with systolic blood pressure Ethics and disseminationThe protocol, informed consent form, participant information sheet and all other participant facing material have been approved by the Research Ethics Committee (South Central—Oxford A; ref 16/SC/0628), Medicines and Healthcare products Regulatory Agency (ref 21584/0371/001–0001), host institution(s) and Health Research Authority. All research outputs will be published in peer-reviewed journals and presented at national and international conferences.Trial registration numberEudraCT 2016-004236-38;ISRCTN97503221; Pre-results.

Details

Database :
OpenAIRE
Journal :
Sheppard, J P, Burt, J, Lown, M, Temple, E, Benson, J, Ford, G A, Heneghan, C, Hobbs, F D R, Jowett, S, Little, P, Mant, J, Mollison, J, Nickless, A, Ogburn, E, Payne, R, Williams, M, Yu, L-M & McManus, R J 2018, ' OPtimising Treatment for MIld Systolic hypertension in the Elderly (OPTiMISE) : protocol for a randomised controlled non-inferiority trial ', BMJ Open, vol. 8, no. 9, e022930 . https://doi.org/10.1136/bmjopen-2018-022930, BMJ Open
Accession number :
edsair.doi.dedup.....bd5891990f28f86e510b3b5dab2d8b66
Full Text :
https://doi.org/10.17863/cam.32492